الفهرس 
Abstract
IntroductionOnly 14 pages are availabe for public view
 |  | from | 34 |  |  |
| | | from | 34 | | |
Abstract
Trihexyphenidyl Hydrochloride (THP) is a tertiary amine antimuscarinic with actions similar to those of atropine. It also has a
direct antispasmodic action on smooth muscle. THP is employed in
the symptomatic treatment of Parkinsonism, including the alleviation
of the extrapyramidal syndrome induced by drugs such as
phenothiazines, but, like other antimuscarinics, is of no value against
tardive dyskinesias. It has been used in the treatment of dystonias.
Trihexyphenidyl Hydrochloride present in the international
market as immediate release tablets, and extended release capsules .A
disadvantage of the capsule, however, is the fact that producing an
extended release capsule formulation is more expensive as compared
to a tablet formulation .The capsule shell has to be bought
additionally, beside extended release pellets manufacturing from point of cost, labor and time compared with tablet manufacturing.
The purpose of this work was to develop a novel extended release tablets containing THP, and to evaluate these tablets according to the official and compendial requirements.